Anti-Diabetic Medications to Fight PD and LBD

Summary

The purpose of this study is to test the hypothesis that DPP4 inhibitors and SGLT2 inhibitors are well tolerated and have beneficial neurological effects, specifically for Parkinson's disease and Lewy body dementia.

Timeline

Start

2024-05-07

Primary completion

2025-01-08

Completion

2025-01-08

Outcome

Mixed primary results

paper a significant difference was found in the change from baseline for MDS-UPDRS part 1 (P = 0.008), part 2 (P = 0.020) PMID 42318251 ↗

paper The dapagliflozin group showed more favorable trends in MDS-UPDRS scores. PMID 42318251 ↗

paper While no significant changes were observed in cognitive scores PMID 42318251 ↗

registry analysis (superiority test); Sitagliptin Group vs Dapagliflozin Group vs Placebo Group; p = 0.67; ANOVA NCT06263673 ↗

registry analysis (superiority test); Sitagliptin Group vs Dapagliflozin Group vs Placebo Group; p = 0.19; ANOVA NCT06263673 ↗

registry analysis (superiority test); Sitagliptin Group vs Dapagliflozin Group vs Placebo Group; p = 0.33; ANOVA NCT06263673 ↗

Publications

• Chmiela T, Dulski J, Heckman MG, Fang ZJ, Wszolek ZK, Wilson JR. Anti-diabetic medications to fight Parkinson's disease and dementia with Lewy bodies: a pilot study. Front Neurol. 2026 May 29;17:1825229. doi: 10.3389/fneur.2026.1825229. eCollection 2026.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dapagliflozin	Small molecule	10 mg	Oral
Subject	Sitagliptin	Small molecule	100 mg	Oral

Indications